Proteins and peptides: Strategies for delivery to and across the skin

Journal of Pharmaceutical Sciences

Volumn 97, Issue 9, 2008, Pages 3591-3610

  Benson, Heather A E ^a   Namjoshi, Sarika ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Dermatology; Electroporation; Iontophoresis; Jet propulsion; Microneedles; Peptide; Protein; Skin penetration enhancement; Sonophoresis; Thermal poration; Transdermal delivery

Indexed keywords

ALPHA INTERFERON; ARGIPRESSIN; CALCITONIN; CYCLOSPORIN; DESMOPRESSIN; DNA VACCINE; GANIRELIX; GLYCOPROTEIN GP 100; GONADORELIN; HEPARIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; INSULIN; LEUPRORELIN; MORPHINE; NAFARELIN; OCTREOTIDE; PEPTIDE; PROTEIN; PROTIRELIN; VIRUS VACCINE;

CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ELECTROPORATION; ENERGY; ERBIUM YAG LASER; HUMAN; IONTOPHORESIS; LASER SURGERY; NEEDLE; NONHUMAN; REVIEW; SKIN PENETRATION; STRATUM CORNEUM; TRANSDERMAL DRUG ADMINISTRATION; ULTRASOUND;

EID: 53549130424     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21277     Document Type: Article

References (140)

1. Bodde HE, Verhoef JC, Ponec M. 1989. Transdermal peptide delivery. Biochem Soc Trans 17:943-945.
2. Loffet A. 2002. Peptides as drugs: Is there a market? J Pept Sci 8:1-7.
3. Namjoshi S, Cacetta R, Benson HAE. 2007. Skin peptides: Biological activity and therapeutic opportunities. J Pharm Sci (DOI: 10.1002/jps. 21198).
4. Higuchi WI. 1962. Analysis of data on the medicament release from ointments. J Pharm Sci 51:802-804.
5. Michaels AS, Chandrasekaran SK, Shaw JE. 1975. Drug permeation through human skin: Theory and in vitro experimental measurement. AIChE 21:985-996.
6. Elias PM, Menon GK. 1991. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 24:1-26.
7. Ogiso T, Iwaki M, Tanino T, Yono A, Ito A. 2000. In vitro skin penetration and degradation of peptides and their analysis using a kinetic model. Biol Pharm Bull 23:1346-1351.
8. Shah PK, Borchardt RT. 1991. A comparison of peptidase activities and peptide metabolism in cultured mouse keratinocytes and neonatal mouse epidermis. Pharm Res 8:70-75.
9. Steinstrasser I, Merkle HP. 1995. Dermal metabolism of topically applied drugs: Pathways and models reconsidered. Pharmaceutica acta Helvetiae. 70:3-24.
10. Benson HAE. 2005. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv 2:23-33.
11. Cross SE, Roberts MS. 2004. Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical developments? Curr Drug Deliv 1:81-92.
12. Schuetz YB, Naik A, Guy RH, Kalia YN. 2005. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2:533-548.
13. Kanikkannan N, Singh M. 2002. Skin permeation enhancement effect and skin irritation of saturated fatty alcohols. Int J Pharm 248:219-228.
14. Magnusson BM, Runn P. 1999. Effect of penetration enhancers on the permeation of the thyrotropin releasing hormone analogue pGlu-3-methyl-His-Pro amide through human epidermis. Int J Pharm 178:149-159.
15. Chen Y, Shen Y, Guo X, Zhang C, Yang W, Ma M, Liu S, Zhang M, Wen LP. 2006. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol 24:455-460.
16. Frankenburg S, Grinberg I, Bazak Z, Fingerut L, Pitcovski J, Gorodetsky R, Peretz T, Spira RM, Skornik Y, Goldstein RS. 2007. Immunological activation following transcutaneous delivery of HR-gp100 protein. Vaccine 25:4564-4570.
17. Foldvari M, Baca-Estrada ME, He Z, Hu J, Attah-Poku S, King M. 1999. Dermal and transdermal delivery of protein pharmaceuticals: Lipid-based delivery systems for interferon alpha. Biotechnol Appl Biochem 30:129-137.
18. Benson HAE. 2006. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv 3:727-737.
19. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. 2000. Ethosomes - Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 65: 403-418.
20. Godin B, Touitou E. 2003. Ethosomes: New prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst 20:63-102.
21. Gupta PN, Mishra V, Rawat A, Dubey P, Mahor S, Jain S, Chatterji DP, Vyas SP. 2005. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: A comparative study. Int J Pharm 293:73-82.
22. Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. 2006. Niosomes as carriers for tretinoin: III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin. Int J Pharm 311:11-19.
23. Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, Gupta PN, Rawat A, Dubey P. 2005. Non-ionic surfactant based vesicles (niosomes) for noninvasive topical genetic immunization against hepatitis B. Int J Pharm 296:80-86.
24. Cevc G. 1996. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 13:257-388.
25. Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G. 1998. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Bio-phys Acta 1368:201-215.
26. Guo J, Ping Q, Zhang L. 2000. Transdermal delivery of insulin in mice by using lecithin vesicles as a carrier. Drug Deliv 7:113-116.
27. Guo J, Ping Q, Sun G, Jiao C. 2000. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm 194:201-207.
28. Brown GL, Curtsinger LJ, White M, Mitchell RO, Pietsch J, Nordquist R, von Fraunhofer A, Schultz GS. 1988. Acceleration of tensile strength of incisions treated with EGF and TGF-beta. Ann Surg 208:788-794.
29. Ghahary A, Tredget EE, Shen Q, Kilani RT, Scott PG, Takeuchi M. 2000. Liposome associated inter-feron-alpha-2b functions as an anti-fibrogenic factor in dermal wounds in the guinea pig. Mol Cell Biochem 208:129-137.
30. Lee JP, Jalili RB, Tredget EE, Demare JR, Ghahary A. 2005. Antifibrogenic effects of liposomeencapsulated IFN-alpha2b cream on skin wounds in a fibrotic rabbit ear model. J Interferon Cytokine Res 25:627-631.
31. Blanchfield JT, Toth I. 2005. Modification of peptides and other drugs using lipoamino acids and sugars. Methods Mol Biol 298:45-61.
32. Caccetta R, Blanchfield JT, Harrison J, Toth I, Benson HAE. 2006. Epidermal penetration of a therapeutic peptide by lipid conjugation; stereoselective peptide availability of a topical diaster-eomeric lipopeptide. Int J Pept Res Ther 12:327-333.
33. Barry BW. 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14:101-114.
34. Delgado-Charro MB, Guy RH. 1994. Characterization of convective solvent flow during iontophoresis. Pharm Res 11:929-935.
35. Heit MC, Monteiro-Riviere NA, Jayes FL, Riviere JE. 1994. Transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH): Effect of repeated administration. Pharm Res 11:1000-1003.
36. Raiman J, Koljonen M, Huikko K, Kostiainen R, Hirvonen J. 2004. Delivery and stability of LHRH and Nafarelin in human skin: The effect of constant/pulsed iontophoresis. Eur J Pharm Sci 21: 371-377.
37. Huang YY, Wu SM, Wang CY. 1996. Response surface method: A novel strategy to optimize iontophoretic transdermal delivery of thyrotropin-releasing hormone. Pharm Res 13:547-552.
38. Boinpally RR, Zhou SL, Devraj G, Anne PK, Poondru S, Jasti BR. 2004. Iontophoresis of lecithin vesicles of cyclosporin A. Int J Pharm 274:185-190.
39. Rodriguez Bayon AM, Guy RH. 1996. Iontophoresis of nafarelin across human skin in vitro. Pharm Res 13:798-800.
40. Lau DT, Sharkey JW, Petryk L, Mancuso FA, Yu Z, Tse FL. 1994. Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (Sandostatin) in the rabbit. Pharm Res 11:1742-1746.
41. Chaturvedula A, Joshi DP, Anderson C, Morris RL, Sembrowich WL, Banga AK. 2005. In vivo iontophoretic delivery and pharmacokinetics of salmon calcitonin. Int J Pharm 297: 190-196.
42. Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK. 2000. Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm 200:107-113.
43. Chien YW, Siddiqui O, Sun Y, Shi WM, Liu JC. 1987. Transdermal iontophoretic delivery of therapeutic peptides/proteins. I: Insulin. Ann N Y Acad Sci 507:32-51.
44. Kalia YN, Naik A, Garrison J, Guy RH. 2004. Iontophoretic drug delivery. Adv Drug Del Rev 56:619-658.
45. Abla N, Naik A, Guy RH, Kalia YN. 2005. Effect of charge and molecular weight on transdermal peptide delivery by iontophoresis. Pharm Res 22: 2069-2078.
46. Abla N, Naik A, Guy RH, Kalia YN. 2005. Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. J Control Release 108:319-330.
47. Schuetz YB, Carrupt PA, Naik A, Guy RH, Kalia YN. 2006. Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. Eur J Pharm Sci 29: 53-59.
48. Schuetz YB, Naik A, Guy RH, Kalia YN. 2005. Effect of amino acid sequence on transdermal iontophoretic peptide delivery. Eur J Pharm Sci 26:429-437.
49. Pillai O, Kumar N, Dey CS, Borkute S, Nagalingam S, Panchagnula R. 2003. Transdermal iontophoresis of insulin. Part 1: A study on the issues associated with the use of platinum electrodes on rat skin. J Pharm Pharmacol 55:1505-1513.
50. Pillai O, Panchagnula R. 2003. Transdermal delivery of insulin from poloxamer gel: Ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J Control Release 89:127-140.
51. Pillai O, Panchagnula R. 2003. Transdermal iontophoresis of insulin. V. Effect of terpenes. J Control Release 88:287-296.
52. Pillai O, Borkute SD, Sivaprasad N, Panchagnula R. 2003. Transdermal iontophoresis of insulin. II. Physicochemical considerations. Int J Pharm 254: 271-280.
53. Pillai O, Panchagnula R. 2004. Transdermal iontophoresis of insulin. VI. Influence of pretreatment with fatty acids on permeation across rat skin. Skin Pharmacol Physiol 17:289-297.
54. Pillai O, Kumar N, Dey CS, Borkute S, Sivaprasad N, Panchagnula R. 2004. Transdermal iontophoresis of insulin: III. Influence of electronic parameters. Methods Find Exp Clin Pharmacol 26:399-408.
55. Pillai O, Nair V, Panchagnula R. 2004. Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers. Int J Pharm 269:109-120.
56. Kari B. 1986. Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin. Diabetes 35:217-221.
57. Tokumoto S, Higo N, Sugibayashi K. 2006. Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin. Int J Pharm 326:13-19.
58. Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S. 2001. Clinical evaluation of the Gluco-Watch biographer: A continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron 16:621-629.
59. Weaver JC. 1993. Electroporation: A general phenomenon for manipulating cells and tissues. J Cell Biochem 51:426-435.
60. Prausnitz MR, Bose VG, Langer R, Weaver JC. 1993. Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 90:10504-10508.
61. Denet A-R, Vanbever R, Preat V. 2004. Skin electroporation for transdermal and topical delivery. Adv Drug Del Rev 56:659-674.
62. Prausnitz MR, Edelman ER, Gimm JA, Langer R, Weaver JC. 1995. Transdermal delivery of heparin by skin electroporation. Biotechnology (NY) 13: 1205-1209.
63. Sen A, Daly ME, Hui SW. 2002. Transdermal insulin delivery using lipid enhanced electroporation. Biochim Biophys Acta 1564:5-8.
64. Sen A, Zhao YL, Hui SW. 2002. Saturated anionic phospholipids enhance transdermal transport by electroporation. Biophys J 83:2064-2073.
65. Sen A, Zhao Y, Zhang L, Hui SW. 2002. Enhanced transdermal transport by electroporation using anionic lipids. J Control Release 82:399-405.
66. Murthy SN, Zhao YL, Marian K, Hui SW, Kazim AL, Sen A. 2006. Lipid and electroosmosis enhanced transdermal delivery of insulin by electroporation. J Pharm Sci 95:2041-2050.
67. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. 2006. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 10: 115-121.
68. Zupanic A, Ribaric S, Miklavcic D. 2007. Increasing the repetition frequency of electric pulse delivery reduces unpleasant sensations that occur in electrochemotherapy. Neoplasma 54:246-250.
69. Miklavcic D, Pucihar G, Pavlovec M, Ribaric S, Mali M, Macek-Lebar A, Petkovsek M, Nastran J, Kranjc S, Cemazar M, Sersa G. 2005. The effect of high frequency electric pulses on muscle contractions and antitumor efficiency in vivo for a potential use in clinical electrochemotherapy. Bioelectrochemistry 65:121-128.
70. Benson HAE, McElnay JC, Harland R. 1989. Use of ultrasound to enhance percutaneous absorption of benzydamine. Phys Ther 69:113-118.
71. Benson HAE, McElnay JC, Harland R, Hadgraft J. 1991. Influence of ultrasound on the percutaneous absorption of nicotinate esters. Pharm Res 8:204-209.
72. Pitt WG, Husseini GA, Staples BJ. 2004. Ultrasonic drug delivery - A general review. Expert Opin Drug Deliv 1:37-56.
73. Mitragotri S, Kost J. 2004. Low-frequency sonophoresis: A review. Adv Drug Del Rev 56:589-601.
74. Alvarez-Roman R, Merino G, Kalia YN, Naik A, Guy RH. 2003. Skin permeability enhancement by low frequency sonophoresis: Lipid extraction and transport pathways. J Pharm Sci 92:1138-1146.
75. Tezel A, Sens A, Mitragotri S. 2003. Description of transdermal transport of hydrophilic solutes during low-frequency sonophoresis based on a modified porous pathway model. J Pharm Sci 92:381-393.
76. Mitragotri S, Blankschtein D, Langer R. 1995. Ultrasound-mediated transdermal protein delivery. Science 269:850-853.
77. Mitragotri S, Kost J. 2001. Transdermal delivery of heparin and low-molecular weight heparin using low-frequency ultrasound. Pharm Res 18: 1151-1156.
78. Smith NB, Lee S, Shung KK. 2003. Ultrasound-mediated transdermal in vivo transport of insulin with low-profile cymbal arrays. Ultrasound Med Biol 29:1205-1210.
79. Park EJ, Werner J, Smith NB. 2007. Ultrasound mediated transdermal insulin delivery in pigs using a lightweight transducer. Pharm Res 24: 1396-1401.
80. Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, Smith W, Soler N, Warsi G, Berg W, Maloney J, Benedetto J, Zhu W, Hohneker J. 2006. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond) 30: 331-341.
81. Liu H, Li S, Pan W, Wang Y, Han F, Yao H. 2006. Investigation into the potential of low-frequency ultrasound facilitated topical delivery of Cyclosporin A. Int J Pharm 326:32-38.
82. Katz NP, Shapiro DE, Herrmann TE, Kost J, Custer LM. 2004. Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Anesth Analg 98:371-376.
83. Singer AJ, Homan CS, Church AL, McClain SA. 1998. Low-frequency sonophoresis: Pathologic and thermal effects in dogs. Acad Emerg Med 5:35-40.
84. Lee S, Kollias N, McAuliffe DJ, Flotte TJ, Doukas AG. 1999. Topical drug delivery in humans with a single photomechanical wave. Pharm Res 16: 1717-1721.
85. Menon GK, Kollias N, Doukas AG. 2003. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J Invest Dermatol 121:104-109.
86. Lee S, McAuliffe DJ, Kollias N, Flotte TJ, Doukas AG. 2002. Photomechanical delivery of 100-nm microspheres through the stratum corneum: Implications for transdermal drug delivery. Lasers Surg Med 31:207-210.
87. Lee S, McAuliffe DJ, Kollias N, Flotte TJ, Doukas AG. 2001. Permeabilization and recovery of the stratum corneum in vivo: The synergy of photomechanical waves and sodium lauryl sulfate. Lasers Surg Med 29:145-150.
88. Lee S, McAuliffe DJ, Mulholland SE, Doukas AG. 2001. Photomechanical transdermal delivery of insulin in vivo. Lasers Surg Med 28:282-285.
89. Lee WR, Shen SC, Liu CR, Fang CL, Hu CH, Fang JY. 2006. Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: An animal study. J Control Release 115:344-353.
90. Tao SL, Popat K, Desai TA. 2006. Off-wafer fabrication and surface modification of asymmetric 3D SU-8 microparticles. Nat Protoc 1:3153-3158.
91. Tao SL, Desai TA. 2005. Micromachined devices: The impact of controlled geometry from cell-targeting to bioavailability. J Control Release 109: 127-138.
92. Tao SL, Desai TA. 2003. Microfabricated drug delivery systems: From particles to pores. Adv Drug Deliv Rev 55:315-328.
93. Henry S, McAllister DV, Allen MG, Prausnitz MR. 1998. Microfabricated microneedles: A novel approach to transdermal drug delivery. J Pharm Sci 87:922-925.
94. Prausnitz MR. 2004. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56:581-587.
95. McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG, Prausnitz MR. 2003. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc Natl Acad Sci USA 100:13755-13760.
96. Martanto W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR. 2004. Transdermal delivery of insulin using microneedles in vivo. Pharm Res 21:947-952.
97. Ito Y, Hagiwara E, Saeki A, Sugioka N, Takada K. 2006. Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 29:82-88.
98. Davis SP, Martanto W, Allen MG, Prausnitz MR. 2005. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng 52:909-915.
99. Cormier M, Johnson B, Ameri M, Nyam K, Libiran L, Zhang DD, Daddona P. 2004. Transdermal delivery of desmopressin using a coated microneedle array patch system. J Control Release 97:503-511.
100. Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K, Daddona PE. 2002. Macro-flux microprojection array patch technology: A new and efficient approach for intracutaneous immunization. Pharm Res 19:63-70.
101. Lin W, Cormier M, Samiee A, Griffin A, Johnson B, Teng CL, Hardee GE, Daddona PE. 2001. Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux) technology. Pharm Res 18:1789-1793.
102. Houdijk EC, Herdes E, Delemarre-Van de Waal HA. 1997. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency. Acta Paediatr 86:1301-1307.
103. Schneider U, Birnbacher R, Schober E. 1994. Pain-fulness of needle and jet injection in children with diabetes mellitus. Eur J Pediatr 153:409-410.
104. Dean HJ, Fuller D, Osorio JE. 2003. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp Immunol Microbiol Infect Dis 26:373-388.
105. Oberye J, Mannaerts B, Huisman J, Timmer C. 2000. Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injections. Hum Reprod 15:245-249.
106. Schramm J, Mitragotri S. 2002. Transdermal drug delivery by jet injectors: Energetics of jet formation and penetration. Pharm Res 19:1673-1679.
107. Kendall M. 2006. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24:4651-4656.
108. Nelson JS, McCullough JL, Glenn TC, Wright WH, Liaw LH, Jacques SL. 1991. Mid-infrared laser ablation of stratum corneum enhances in vitro percutaneous transport of drugs. J Invest Dermatol 97:874-879.
109. Lee WR, Shen SC, Fang CL, Liu CR, Fang JY. 2007. Skin pretreatment with an Er:YAG laser promotes the transdermal delivery of three narcotic analgesics. Lasers Med Sci 22:271-278.
110. Fang JY, Lee WR, Shen SC, Wang HY, Fang CL, Hu CH. 2004. Transdermal delivery of macromo-lecules by erbium:YAG laser. J Control Release 100:75-85.
111. Lee WR, Shen SC, Wang KH, Hu CH, Fang JY. 2002. The effect of laser treatment on skin to enhance and control transdermal delivery of 5-fluorouracil. J Pharm Sci 91:1613-1626.
112. Lee WR, Shen SC, Lai HH, Hu CH, Fang JY. 2001. Transdermal drug delivery enhanced and controlled by erbium:YAG laser: A comparative study of lipophilic and hydrophilic drugs. J Control Release 75:155-166.
113. Birchall J, Coulman S, Anstey A, Gateley C, Sweetland H, Gershonowitz A, Neville L, Levin G. 2006. Cutaneous gene expression of plasmid DNA in excised human skin following delivery via microchannels created by radio frequency ablation. Int J Pharm 312:15-23.
114. Sintov AC, Krymberk I, Daniel D, Hannan T, Sohn Z, Levin G. 2003. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. J Control Release 89:311-320.
115. Levin G, Gershonowitz A, Sacks H, Stern M, Sherman A, Rudaev S, Zivin I, Phillip M. 2005. Transdermal delivery of human growth hormone through RF-microchannels. Pharm Res 22:550-555.
116. Svedman P, Lundin S, Hoglund P, Hammarlund C, Malmros C, Pantzar N. 1996. Passive drug diffusion via standardized skin mini-erosion; methodological aspects and clinical findings with new device. Pharm Res 13:1354-1359.
117. Westerling D, Hoglund P, Lundin S, Svedman P. 1994. Transdermal administration of morphine to healthy subjects. Br J Clin Pharmacol 37:571-576.
118. Svedman P, Lundin S, Svedman C. 1991. Administration of antidiuretic peptide (DDAVP) by way of suction de-epithelialised skin. Lancet 337:1506-1509.
119. Eppstein JA, Hatch MR, Papp J. 2004. Apparatus for microporation of biological membranes using thin film tissue interface devices, and methods therefor. Altea Therapeutics Corporation US Patent 6692456.
120. Badkar AV, Smith AM, Eppstein JA, Banga AK. 2007. Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats. Pharm Res 24:1389-1395.
121. Patel YR. 2006. Altea therapeutics transdermal PassPort system: Freedom from insulin injections for superior diabetes management http://www. ondrugdelivery. com.
122. Garg S, Hoelscher M, Belser JA, Wang C, Jayashankar L, Guo Z, Durland RH, Katz JM, Sambhara S. 2007. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice. Clin Vaccine Immunol 14:926-928.
123. Mitragotri S. 2000. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res 17: 1354-1359.
124. Barry BW. 2004. Breaching the skin's barrier to drugs. Nat Biotechnol 22:165-167.
125. Karande P, Jain A, Mitragotri S. 2004. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol 22:192-197.
126. Karande P, Jain A, Mitragotri S. 2006. Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery. J Control Release 115:85-93.
127. Karande P, Mitragotri S. 2002. High throughput screening of transdermal formulations. Pharm Res 19:655-660.
128. Srinivasan V, Su MH, Higuchi WI, Behl CR. 1990. Iontophoresis of polypeptides: Effect of ethanol pretreatment of human skin. J Pharm Sci 79: 588-591.
129. Choi EH, Lee SH, Ahn SK, Hwang SM. 1999. The pretreatment effect of chemical skin penetration enhancers in transdermal drug delivery using iontophoresis. Skin Pharmacol Appl Skin Physiol 12:326-335.
130. Bhatia KS, Gao S, Freeman TP, Singh J. 1997. Effect of penetration enhancers and iontophoresis on the ultrastructure and cholecystokinin-8 permeability through porcine skin. J Pharm Sci 86: 1011-1015.
131. Mitragotri S, Ray D, Farrell J, Tang H, Yu B, Kost J, Blankschtein D, Langer R. 2000. Synergistic effect of low-frequency ultrasound and sodium lauryl sulfate on transdermal transport. J Pharm Sci 89:892-900.
132. Kushner J, Kim D, So PT, Blankschtein D, Langer RS. 2007. Dual-channel two-photon microscopy study of transdermal transport in skin treated with low-frequency ultrasound and a chemical enhancer. J Invest Dermatol 127:2832-2846.
133. Lavon I, Grossman N, Kost J. 2005. The nature of ultrasound-SLS synergism during enhanced transdermal transport. J Control Release 107: 484-494.
134. Bommannan DB, Tamada J, Leung L, Potts RO. 1994. Effect of electroporation on transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH) in vitro. Pharm Res 11:1809-1814.
135. Medi BM, Singh J. 2003. Electronically facilitated transdermal delivery of human parathyroid hormone (1-34). Int J Pharm 263:25-33.
136. Le L, Kost J, Mitragotri S. 2000. Combined effect of low-frequency ultrasound and iontophoresis: Applications for transdermal heparin delivery. Pharm Res 17:1151-1154.
137. Daniels R. 2004. Strategies for Skin Penetration Enhancement. Skin Care Forum (wwwscf-onlinecom) 37.
138. Furness G. 2003. Global overview of the active transdermal drug delivery market. Drug Delivery Technology 4: www.drugdeliverytech.com.
139. Mishra D, Dubey V, Asthana A, Saraf DK, Jain NK. 2006. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine 24:4847-4855.
140. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G, Vessey R, King A, Ogg G, Gallimore A, Haynes JR, Heydenburg Fuller D. 2000. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19:764-778.